ALLERGY, IMMUNOLOGY AND RELATED DISORDERS: Edited by Jordan S. OrangeHereditary angioedema in children: a review and updatePancholy, Nehaa; Craig, TimothybAuthor Information aDepartment of Medicine bDepartment of Medicine and Pediatrics at Penn State University, College of Medicine, Hershey, Pennsylvania, USA Correspondence to Timothy Craig, Department of Medicine and Pediatrics at Penn State University, College of Medicine, Hershey, PA, USA. Tel: +1 717 531 0000; e-mail: [email protected] Current Opinion in Pediatrics: December 2019 - Volume 31 - Issue 6 - p 863-868 doi: 10.1097/MOP.0000000000000832 Buy Metrics Abstract Purpose of review Hereditary angioedema (HAE) most often presents in the first two decades of life. Despite these patients often see multiple doctors and go many years before confirmation of the diagnosis. the impact on quality of life, productivity and risk of anxiety, depression, and posttraumatic stress emphasizes the need for early diagnosis and appropriate treatment. Recent findings Over the past decade, therapy in the USA has emerged from fresh-frozen plasma and androgens to more than seven medications that are specific for bradykinin-induced disease. During the same time, treatment has evolved from intravenous to subcutaneous and the future will be a focus on oral therapy. Summary Much optimism exists that patients with HAE will live a life with minimal disease and impact on their quality of life making it even more important to diagnose children at an early age. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.